XTL Biopharmaceuticals Statistics

Total Valuation

XTL Biopharmaceuticals has a market cap or net worth of ILS 105.27 million. The enterprise value is 96.64 million.

Market Cap	105.27M
Enterprise Value	96.64M

Important Dates

The next estimated earnings date is Tuesday, November 12, 2024.

Earnings Date	Nov 12, 2024
Ex-Dividend Date	n/a

Share Statistics

XTL Biopharmaceuticals has 1.22 billion shares outstanding.

Shares Outstanding	1.22B
Shares Change (YoY)	n/a
Shares Change (QoQ)	+0.01%
Owned by Insiders (%)	10.75%
Owned by Institutions (%)	2.16%
Float	1.09B

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
PB Ratio	4.69
P/FCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-69.25
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 11.43

Current Ratio	11.43
Quick Ratio	10.49
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -13.07% and return on invested capital (ROIC) is -14.89%.

Return on Equity (ROE)	-13.07%
Return on Assets (ROA)	-13.78%
Return on Capital (ROIC)	-14.89%
Revenue Per Employee	n/a
Profits Per Employee	-279,115
Employee Count	5
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +24,757.14% in the last 52 weeks. The beta is 0.88, so XTL Biopharmaceuticals's price volatility has been lower than the market average.

Beta (5Y)	0.88
52-Week Price Change	+24,757.14%
50-Day Moving Average	9.70
200-Day Moving Average	6.54
Relative Strength Index (RSI)	34.74
Average Volume (20 Days)	635,105

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-2.54M
Pretax Income	-1.40M
Net Income	-1.40M
EBITDA	n/a
EBIT	-2.54M
Earnings Per Share (EPS)	-0.00

Full Income Statement

Balance Sheet

Cash & Cash Equivalents	8.64M
Total Debt	n/a
Net Cash	8.64M
Net Cash Per Share	0.01
Equity (Book Value)	9.99M
Book Value Per Share	0.02
Working Capital	8.58M

Full Balance Sheet

Cash Flow

Operating Cash Flow	n/a
Capital Expenditures	n/a
Free Cash Flow	n/a
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

XTL Biopharmaceuticals does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	n/a
Shareholder Yield	n/a
Earnings Yield	n/a
FCF Yield	n/a

Stock Splits

The last stock split was on June 22, 2009. It was a reverse split with a ratio of 0.2.

Last Split Date	Jun 22, 2009
Split Type	Reverse
Split Ratio	0.2

Scores

Altman Z-Score	n/a
Piotroski F-Score	n/a